(Q48322904)

English

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

scientific article published on 7 January 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C Mamolo

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

J Harness

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

H Tan

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

A Menter

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

publication date

7 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

Journal of the European Academy of Dermatology and Venereology

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

28

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

192-203

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

The contribution of perceptions of stigmatisation to disability in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Quality-of-life issues in psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Psoriasis causes as much disability as other major medical diseases

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12081

21 January 2018

Identifiers

10.1111/JDV.12081

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/23294276

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48322904&oldid=2195205756"